Response rates and MRD according to CT scan and bone marrow examination
| CT . | 3 mo . | 6 mo . | 1.5 mo after completed therapy . |
|---|---|---|---|
| ORR (%) | 88.0 | 80.0 | 64.0 |
| CR/CRU | 24 (48%) | 32 (64%) | 31 (62%) |
| PR | 20 | 8 | 1 |
| PD | 1 | 3 | 8 |
| Not evaluated* | 5 | 7 | 10 |
| Total | 50 | 50 | 50 |
| MRD-negativity | 3 mo | 6 mo | 12 mo |
| BM | 18 (50%) | 18 (56%) | 16 (64%) |
| PB | 23 (61%) | 21 (68%) | 19 (80%) |
| Evaluated BM/PB | 36/38 | 32/31 | 25/24 |
| MRD-negativity (based on intention to treat) | 3 mo | 6 mo | 12 mo |
| BM | 18 (36%) | 18 (36%) | 16 (32%) |
| PB | 23 (46%) | 21 (42%) | 19 (38%) |
| Total | 50 | 50 | 50 |
| CT . | 3 mo . | 6 mo . | 1.5 mo after completed therapy . |
|---|---|---|---|
| ORR (%) | 88.0 | 80.0 | 64.0 |
| CR/CRU | 24 (48%) | 32 (64%) | 31 (62%) |
| PR | 20 | 8 | 1 |
| PD | 1 | 3 | 8 |
| Not evaluated* | 5 | 7 | 10 |
| Total | 50 | 50 | 50 |
| MRD-negativity | 3 mo | 6 mo | 12 mo |
| BM | 18 (50%) | 18 (56%) | 16 (64%) |
| PB | 23 (61%) | 21 (68%) | 19 (80%) |
| Evaluated BM/PB | 36/38 | 32/31 | 25/24 |
| MRD-negativity (based on intention to treat) | 3 mo | 6 mo | 12 mo |
| BM | 18 (36%) | 18 (36%) | 16 (32%) |
| PB | 23 (46%) | 21 (42%) | 19 (38%) |
| Total | 50 | 50 | 50 |
CR, complete remission; CRu, complete remission undetermined; ORR, overall response rate; PD, progressive disease; PR, partial remission.
Not evaluated: death of any cause, consent withdrawn, end of study because of something other than PD, end of treatment owing to any cause and not evaluated at this time point, not done of other cause/missing data.